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Edited by Takashi GojoboriAbstract The use of long double-stranded RNA (dsRNA) for
gene silencing in mammalian cells has generally been restricted
to embryonic cell types and proposed to induce non-speciﬁc
eﬀects on gene expression in diﬀerentiated cells. In this study, we
report that foreign and endogenous gene expression can be
regulated in immortalised human cell lines by co-expression of
long complementary RNAs with the potential to form dsRNA.
The observed gene silencing eﬀect was transferable to recipient
control cells, occurred independently of cytoplasmic Dicer and
produced an epi-allelic series of clones suitable for gene function
studies. This complementary RNA co-expression approach
permits the use of long complementary RNAs for regulating
speciﬁc gene expression in mammalian cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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silencing1. Introduction
The introduction of double-stranded RNA (dsRNA) into a
range of organisms induces both a potent and speciﬁc gene si-
lencing eﬀect [1,2]. This form of gene suppression by a dsRNA
molecule was ﬁrst observed in Caenorhabditis elegans and given
the term RNA interference or RNAi [3]. Subsequent studies
have shown that dsRNA is an eﬀective inducer of gene silencing
in awide range of eukaryotic organisms and that themechanism
behind this form of gene regulation is most likely conserved
throughout evolution. The molecular mechanism of RNAi has
begun to be deciphered using biochemical and genetic ap-
proaches in diﬀerent experimental systems. Presently, RNAi is
postulated to involve both an initiation step and an eﬀector step
[4]. During the initiation phase, dsRNA is processed by the
RNaseIII family nuclease Dicer to produce 21–23 nucleotide
duplex small interfering RNAs (siRNAs) [5]. In the eﬀector
phase, these siRNAs are incorporated into a multiprotein* Corresponding author. Fax: +61-2-8396-5811.
E-mail address: garndt@medau.jnj.com (G.M. Arndt).
Abbreviations: dsRNA, double-stranded RNA; siRNA, small interfer-
ing RNA; RISC, RNA-induced silencing complex; shRNA, short
hairpin RNA; bp, base pair; ORF, open reading frame; RSV, rous
sarcoma virus; CMV, cytomegalovirus; LTR, long terminal repeat
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.07.075complex called RNA-induced silencing complex (RISC) that
targets transcripts by base pairing between one of the siRNA
strands and the endogenous mRNA. A nuclease activity asso-
ciated with the RISC complex then cleaves the mRNA–siRNA
duplex thus targeting the cognate mRNA for destruction [6].
In general, RNAi-mediated interference of gene expression
in mammalian cells is accomplished using synthetic siRNAs [5]
or gene constructs expressing short hairpin RNAs (shRNAs)
[7]. One alternative to shRNA constructs is transcription of
siRNA sense and antisense strands via a convergent promoter
system [8]. The use of longer dsRNA to reduce gene expression
has been hampered by the presence of a unique global response
mechanism. Unlike other organisms, mammalian cells exposed
to dsRNA longer than 30 base pairs (bp) in length have been
predicted to undergo a response mechanism involving activa-
tion of two key enzymes, dsRNA-activated protein kinase
(PKR) and 20-50 oligoadenylate polymerase/RnaseL [9]. The
activation of these enzymes leads to an inactivation of protein
synthesis and eventually cell death via apoptosis. It was thus
anticipated that the introduction of long dsRNA would acti-
vate this global response system. However, studies have shown
that in both mouse pre-implantation embryos and undiﬀer-
entiated embryonic stem cells and embryonic carcinoma cells,
the use of in vitro generated long dsRNA was able to mediate
speciﬁc gene silencing [10–12]. In addition, RNAi-like activity
was demonstrated using gene constructs designed to encode
long inverted repeat RNAs [13]. The primary reason provided
for these observations was that these cell systems lack the
generalised responses to dsRNA. The above results were en-
couraging but placed particular limitations on the utility of
these approaches in mammalian cell types containing active
and robust generalised dsRNA responses.
The most popular approach to gene silencing in non-mam-
malian cells is the use of long dsRNA. Processing of the long
dsRNA produces a pool of siRNAs overcoming any issues
associated with target RNA accessibility. Attempts to deliver
long dsRNA to the cytoplasm of diﬀerentiated mammalian
cells have been disappointing due to the activation of the in-
terferon-like response [14]. Despite these observations, several
lines of evidence suggest that dsRNAs longer than 30 bp exist
in mammalian cells and that these species mediate gene si-
lencing. First, a number of studies in mammalian cells using
long antisense RNAs, expressed from genes integrated in the
genome, mediate suppression by target RNA degradation,
suggesting a dsRNA intermediate. Second, studies using senseblished by Elsevier B.V. All rights reserved.
Fig. 1. Complementary RNA co-expression vectors speciﬁc for dE-
GFP. Two sets of episomal plasmids were constructed using pEAK10
(JJR) and pREP7 as the core vector backbones. (A) pJEctgES;
(B) pJEAs; (C) pR7ctgES; (D) pR7ctgEaS. Plasmids pEAK10 (JJR)
and pREP7 contain the elongation factor 1a (EF1a; ﬁlled arrrow) and
Rous sarcoma virus (RSV; hatched arrows) promoters, respectively,
controlling expression of dEGFP-speciﬁc RNAs. Selectable markers
conferring resistance to either puromycin or hygromycin are indicated.
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dsRNAs can be tolerated in mammalian cells [15]. Third, gene-
expressed self-complementary RNAs of 400 nucleotides have
been shown to be eﬀective at speciﬁc gene control in neuronal
cells [16]. Finally, nuclear-directed long antisense RNA, or
inverted repeat dsRNA, mediates speciﬁc gene silencing in
cultured cells and mice without eliciting a global response [17].
Further evidence for extensive long dsRNA species in mam-
malian cells comes from sequencing of the human genome
which revealed that as much as 8% of the expressed mRNAs
have a corresponding antisense RNA complement of between
200 and 3000 bp [18]. These observations suggest that condi-
tions exist in which long complementary RNAs can direct
speciﬁc gene silencing in mammalian cells.
In this study, we report on the development of a methodol-
ogy for expressing long complementary RNAs in mammalian
cells, with the potential to form dsRNA and regulate speciﬁc
gene expression. We show that this approach can be used to
suppress both a transgene and endogenous genes. The sup-
pressive eﬀect reduces both target mRNA steady state levels
and the adundance of the encoded gene product. The observed
regulatory event is dependent on the co-expression of comple-
mentary RNA strands, does not activate PKR or other cellular
stress responses, is not dependent on Dicer for maintenance of
gene silencing, and produces intermediate gene-speciﬁc siR-
NAs. Furthermore, the silencing eﬀect is shown to be trans-
ferable to other mammalian cells in culture. We demonstrate
that this strategy can be used to generate an ‘‘epi-allelic’’ series
of mutants useful in functional analysis of speciﬁc genes. It is
anticipated that this method will be extremely useful for con-
trolling speciﬁc gene expression in mammalian cells.2. Materials and methods
2.1. Construction of episomal expression vectors
Standard gene cloning methods were used to construct expression
plasmids used in the present study. The plasmids used in the co-
transfection experiments were based in the core episomal plasmids
pREP7 (Invitrogen) or pEAK10(JJR) (Edge Biosystems). These plas-
mids are maintained within the nucleus and do not generally integrate
into the genomic DNA. The sequences required for episomal plasmid
maintenance are the Epstein Barr virus OriP and EBNA1 regions. The
portion of the dEGFP target gene used to construct the sense and
antisense dEGFP-expressing plasmids in pREP7 spanned positions 666
to 1749 in reference to the pd4EGFP-N1 (Clontech) sequence map.
This region was PCR-ampliﬁed using pd4EGFP-N1 as a template and
the following primers: 50 TGA GGA TTC ACC GGT CGC CAC CCT
GGT GAG CAA G 30 and 50 TGA GGA TTC ACA AAC CAC AAC
TAG AAT GCA GTG 30. The base change indicated by C was in-
troduced to eliminate the ATG start codon and ensure that sense
dEGFP RNA was not translated. The 1083 bp PCR product was di-
gested with BamHI and subcloned into the unique BamHI site in
pREP7 downstream of the RSV long terminal repeat (LTR) promoter
in the sense and antisense orientations to produce pR7ctgES and
pR7ctgEaS, respectively. The dEGFP insert in plasmid pJEAs was
obtained by PCR amplifying the entire transcription unit of the dE-
GFP gene spanning positions 583 to 1749 (in reference to the
pd4EGFP-N1 sequence map) using the following PCR primers: 50
TCA GAT CCG CTA GCG CTA CCG GAC 30 and 50 ACA AAC
CAC AAC TAG AAT GCA GTG 30. This fragment was ligated to
BamHI adaptors created by annealing the following single-stranded
oligonucleotides: 50 TCT CTA GGG ATC CTC AGT CAG TCA
GGA TG 30 and 50 CAT CCT GAC TGA CTG AGG ATC CCT
AGA GAA TA 30. The adaptor-ligated fragment was then digested
with BamHI and ligated into the unique BglII site in pEAK10(JJR) in
the antisense orientation relative to the mammalian protein elongation
factor 1a promoter to produce pJEAs. For construction of the plasmidpJctgES, the region of the dEGFP gene in pd4EGFP-N1 spanning
positions 666 to 1749 was PCR-ampliﬁed using the forward primer 50
TGA AGA TCT ACC GGT CGC CAC CCT GGT GAG CAA G 30
and the reverse primer 50 TGA GAA TTC ACA AAC CAC AACTAG
AAT GCA GTG 30. The BglII–EcoRI digested PCR product was di-
rectionally cloned in the sense direction downstream of the elongation
factor 1a promoter of pEAK10(JJR) to produce pJctgES. The sense
and antisense dEGFP genes contained on pR7ctgES, pR7ctgEaS,
pJEAs, and pJctgES are indicated schematically in Fig. 1.
To construct the complementary RNA co-expression vectors speciﬁc
for the endogenous TP53 gene, the open reading frame (ORF) was
PCR-ampliﬁed from pORF53 (Invivogen) using the following forward
and reverse primers: 50 GCG CAA GCT TCT GGA GGA GCC GCA
GTC ATG 30 and 50 GCG CAA GCT TTC AGT CTG AGT CAG
GCC CCT 30. This 1195 bp PCR product was digested with HindIII
and subcloned in the antisense orientation downstream of the RSV
LTR promoter in pREP7 and in the sense direction downstream of the
elongation factor 1a promoter in pEAK10(JJR).
2.2. Construction of dEGFP-expressing cell line
The derivative cell line expressing the dEGFP target gene was con-
structed by electroporating EcR293 cells (Invitrogen) with the plasmid
pd4EGFP-N1 (Clontech) linearised with AﬂII. The transfected cell
population was selected in the presence of 500 lg/ml G418 and clones
expanded and screened for dEGFP expression by ﬂuorescence-acti-
vated cell sorting (FACs) analysis using the Becton Dickinson FAC-
SORT. This cell line, expressing dEGFP under control of the
cytomegalovirus (CMV) immediate early promoter, was previously
shown to contain a single copy of the dEGFP expression cassette using
Southern blot analyses [19].
2.3. Cell culture and methods
EcR293 human embryonic kidney cells (Invitrogen) and HCT116
colon carcinoma cells were maintained in DMEM containing 10%
foetal calf serum and supplemented with glutamine, streptomycin and
penicillin. To generate pooled populations containing two diﬀerent
episomal vectors, 2.5  106 dEGFP-expressing cells or HCT116 cells
were electroporated with 2.5 lg of each plasmid. At 48 hours after
transfection, cells were exposed to 0.7 lg/ml of puromycin (to select for
pEAK10(JJR)-based plasmids) and 100 lg/ml hygromycin (to select
for pREP7-based plasmids). Following 28 days of double selection,
cells were then exposed to 500 lg/ml of G418. At ﬁve weeks post-
electroporation, each of the selected pooled populations was charac-
terised for dEGFP-mediated cell ﬂuorescence, dEGFP protein level
and steady-state level of dEGFP mRNA. To isolate individual clones,
pooled populations were serially diluted. Transfection of mammalian
cells with siRNAs was performed as previously described [8]. The
Dicer-speciﬁc and nonsense control siRNA sequences were 50-UGC
N. Tran et al. / FEBS Letters 573 (2004) 127–134 129UUG AAG CAG CUC UGG A-30 (sense) and 50-GCG CGC TTT
GTA GGA TTC G-30 (sense), respectively.
2.4. Protein and RNA analyses
Cell lysates were prepared using RIPA buﬀer supplemented with
protease inhibitors aprotonin (1 lg/ml), leupeptin (10 lg/ml) and
DMSF (100 lg/ml). A total of 60 lg of total protein was loaded onto
pre-cast 10% agarose Tris–HCl gels (BioRad). Proteins were separated
by electrophoresis and transferred to PVDF membrane (Millipore).
The antibodies used to detect speciﬁc proteins included: GFP mouse
polyclonal (Clontech), PKR, PKR Phospho-rabbit polyclonal (Cell
Signaling), p53, p21 mouse monoclonal (Oncogene Research Products)
or b-actin mouse monoclonal (Sigma) antibodies. Secondary antibody
detection was performed using either the goat anti-mouse (horseradish
peroxidase (HRP)-linked) or the goat anti-rabbit HRP (Santa Cruz),
followed by visualisation using the luminol/enhancer chemiluminescent
substrate (Amersham).
Northern blot analysis was used to determine the steady-state levels
of dEGFP and p53 mRNAs. Total RNA isolated using Trizol reagent
(Life Technologies) was separated on a 1% agarose–formaldehyde gel
and transferred to a nylon charged membrane. DNA fragments con-
taining the ORFs for either dEGFP or p53 were used as probes. De-
tection of small p53-speciﬁc RNAs was achieved using a hydrolysed
p53 RNA probe as previously described [20]. This RNA was generated
by in vitro transcription using pORF53 and the MegaScript Kit
(Ambion) according to the manufacturer’s instructions.
2.5. Media transfer experiments
To examine the eﬀect of the culture medium on dEGFP-mediated
cell ﬂuorescence, control cells and cells co-expressing antisense and
sense dEGFP RNA were each seeded in three media types: control cell
conditioned medium, sense/antisense cell conditioned medium and
unconditioned DMEM. After two and ﬁve days in each of these media,
both control cells and cells co-expressing antisense and sense dEGFP
RNA were assayed for cell ﬂuorescence and dEGFP, p53 and b-actin
protein levels.Fig. 2. Suppressing dEGFP gene expression by co-expression of long
complementary RNAs. (A) Reduction of dEGFP-mediated cell ﬂuo-
rescence in EcR293 cells containing sense and antisense dEGFP-ex-
pressing plasmids. The three sets of histograms (control, S, AS, and
S+AS) represent cells that are 50%, 70% and 90% conﬂuent. Each
histogram is the average of three experiments and error bars represent
S.D. The abbreviations are as follows: control¼ vectors alone;
S¼ sense vector; AS¼ antisense vector and S+AS¼ sense and anti-
sense vectors. (B) Reduction of dEGFP protein levels in cells co-ex-
pressing long complementary RNAs. (C) Cells co-transfected with
sense and antisense dEGFP episomal plasmids do not activate PKR.
The steady-state levels of PKR (PKR), activated PKR (PKRP) and b-
actin is shown. The PKR control and PKRP control samples represent
HeLa cells untreated and treated with 0.1 lM of calyculin.3. Results
3.1. Co-expression of sense and antisense RNA suppresses
transgene expression
A human embryonic kidney cell line stably expressing the
dEGFP gene under control of the CMV immediate early
promoter (and G418 resistant due to the presence of a linked
neomycin phosphotransferase gene) was transfected with epi-
somal plasmids containing either the gene conferring resistance
to hygromycin or the gene conferring resistance to puromycin,
and sense and antisense expression cassettes. The structure of
the dEGFP-speciﬁc plasmids used to express antisense com-
plementary to the target mRNA or sense RNA homologous to
the target mRNA is outlined in Fig. 1. The ATG start codon in
the sense gene was modiﬁed to prevent translation of the
encoded sense RNA into dEGFP protein. Following co-
transfection with the sense and antisense plasmids, cells con-
taining both episomes and the target gene were selected using
puromycin, hygromycin and G418. The control cells contained
the two core vectors without antisense or sense genes, while the
cells containing the antisense plasmid or sense plasmid only
were co-transfected with the appropriate core vector contain-
ing the second selectable marker. In this way, all cells selected
were resistant to puromycin, hygromycin and G418.
After selection, all co-transfectants were subcultured, grown
and analysed for their cell ﬂuorescence proﬁle (Fig. 2A). Cells
containing the vectors alone, the antisense plasmid alone or the
sense plasmid alone did not display a reduction in dEGFP-
mediated cell ﬂuorescence. This outcome was observed using
antisense or sense genes controlled by either the mammalianconstitutive EF1a promoter or RSV LTR. In contrast, cells
containing both the antisense and sense plasmids revealed an
approximately 40–60% reduction in cell ﬂuorescence mediated
by the dEGFP target gene. These data show that co-expression
of antisense and sense RNAs, in the presence of the target
mRNA, is more eﬀective at suppressing the cellular phenotype
associated with expression of the target gene in human cells
than using an antisense or a sense plasmid alone. This suggests
that introducing two complementary RNAs, with the potential
to form intermolecular dsRNA, into human cells can regulate
the expression of a speciﬁc gene.
To examine the impact of co-expressing these complemen-
tary RNAs on the level of dEGFP protein, total protein was
extracted from the above cells and analysed for the expression
of the following gene products: dEGFP and b-actin (Fig. 2B).
This analysis indicated that the level of dEGFP protein was
reduced by 50% in cells co-expressing complementary RNAs.
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Fig. 3. Generation of an epi-allelic series of clones displaying diﬀerent
dEGFP target gene expression proﬁles. (A) Diﬀerential regulation of
dEGFP-mediated cell ﬂuorescence in cells containing sense and anti-
sense plasmids. The geometric mean ﬂuorescence for diﬀerent EcR293
clones containing sense and antisense (S+AS), antisense (AS), sense
(S) or vector (control) plasmids are shown. The clones containing sense
and antisense plasmids are classiﬁed into three classes (I, II and III).
(B) Gene silencing through complementary RNA co-expression is
Dicer-independent. Representative class II clones (clones 12 and 7) and
a control clone (clone 8) were transfected with either no siRNA
(mock), Dicer siRNA (Dicer) or nonsense siRNA (nonsense) and
monitored for geometric mean ﬂuorescence. Each histogram is the
average of three experiments and error bars represent S.D.
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cells expressing either sense or antisense RNA alone. This result
indicated that the observed phenotypic change in cell ﬂuores-
cence in the antisense and sense RNA co-expressing cells was
due to the reduction in the steady-state level of dEGFP protein.
One of the potential limitations associated with using longer
dsRNA in mammalian cells is the activation of PKR and the
downstream eﬀects [21]. In this study, we observed no abnor-
mal changes in cell morphology and no signiﬁcant decrease in
cell density (data not shown). Furthermore, we were unable to
detect the phosphorylated version of an active PKR in our
cells expressing complementary RNAs (Fig. 2C). Studies have
suggested that p53 is an important mediator of dsRNA-in-
duced gene expression [22]. In the present study, we observed
no increase in the steady-state levels of p53 protein and no
activation of p53, as measured by the presence of p21, a
downstream indicator of p53 transcriptional activity (data not
shown). These results suggest that the presence of sense and
antisense RNA-expressing plasmids within the same cell does
not activate the global response mechanism or a general cel-
lular stress signal mediated by p53 activation.
3.2. Complementary RNA co-expression produces clones with
diﬀerent levels of target gene expression
To examine the level of dEGFP gene suppression mediated
within the pooled population, we selected clones containing
sense, antisense or both sense and antisense dEGFP RNA-
expressing plasmids. Analysis of cell ﬂuorescence indicated
that a greater number of clones containing the sense and an-
tisense plasmids displayed reduced ﬂuorescence. These clones
could be arranged into three diﬀerent classes based on the
degree of reduction in cell ﬂuorescence. Class I displayed no
reduction, class II displayed intermediate levels and class III
showed negligible levels of cell ﬂuorescence (Fig. 3A). This
method for regulating speciﬁc gene expression produces a se-
ries of single clones that display varying degrees of target gene
expression – a most desirable tool for examining gene function.
One possible mechanism by which long complementary
RNAs may operate is through the formation of long dsRNA
that undergoes processing by the RNAse III-like enzyme Dicer
to produce small dsRNAs that act as the eﬀectors of gene si-
lencing [23]. To determine whether Dicer was required for the
maintenance of gene silencing, we used RNAi to reduce the
expression of Dicer [24]. Reduction of Dicer in either class II
or III clones did not reverse silencing of the dEGFP transgene,
suggesting that the observed gene suppression was Dicer-
independent (Fig. 3B). This result does not eliminate the
possibility that a Dicer-like activity, not recognised by Dicer-
speciﬁc siRNAs, was not involved [25].
3.3. The gene silencing eﬀect induced by long complementary
RNAs is transferable
It has been noted in earlier studies using dsRNA as a me-
diator of gene inactivation in non-mammalian cells that a
proportion of the suppressive eﬀect can be transferred to
other cells in vivo [26] or in culture [27]. To examine the
transferability of the dEGFP-speciﬁc dsRNA-mediated sup-
pressive eﬀect, we conducted a culture medium exchange ex-
periment (Fig. 4A). Conditioned media from control cells and
cells co-expressing antisense and sense dEGFP RNA were
isolated and used to culture cells co-expressing antisense and
sense dEGFP RNA and control cells, respectively. Controlcells cultured in medium isolated from cells co-expressing
antisense and sense dEGFP RNA displayed a reduction in
dEGFP-mediated cell ﬂuorescence (Fig. 4B). In contrast, the
addition of conditioned control medium or unconditioned
DMEM to these cells did not produce the same reduction in
cell ﬂuorescence, suggesting that the silencing eﬀect was spe-
ciﬁc and did not result from depletion of nutrients. Similar
trends were observed in sense and antisense plasmid-
containing cells exposed to unconditioned DMEM and re-
exposed to conditioned medium derived from sense and
antisense RNA-expressing cells (Fig. 4B). These results sug-
gest that the suppressive eﬀect generated within human cells
by co-expressing sense and antisense RNA was transferable to
cells that had not been previously exposed to either the sense
or antisense RNAs. The fact that the suppressive eﬀect was
not transferable to all cells within the original culture, or the
recipient culture, suggests that other factors inﬂuence the
transferability of the silencing eﬀect between cells induced by
complementary RNA co-expression.
To examine the speciﬁcity of the mobile silencing eﬀect, the
levels of the dEGFP protein were determined. As shown in
Fig. 4C, only control cells receiving cultured medium from the
Fig. 5. Complementary RNA co-expression mediates speciﬁc reduction
of the p53 protein in HCT116 colon cancer cells. (A) Western blot
analysis of p53 and b-actin protein levels in stable clones containing
sense and antisense, antisense, sense or control plasmids. The histo-
grams represent the ratio of p53 to b-actin in each clone and clones are
numbered on the horizontal axis. The p53:b-actin ratios for clones
containing the sense and antisense p53 plasmids are indicated by
hatched histograms. (B) Suppression of p53 protein correlates with p53
mRNA levels. Northern blot analysis of p53 mRNA and 18S rRNA in
selected clones identiﬁed in (A). (C) Induction of gene silencing by long
complementary RNA generates p53-speciﬁc small RNAs. Northern
blot analysis of p53-speciﬁc small RNAs and tRNAvaline in selected
clones identiﬁed in A and B. The arrow indicates the small p53-speciﬁc
RNAs in S+AS clones 4 and 9.
Fig. 4. Transferability of the speciﬁc gene-silencing signal induced by
complementary RNA co-expression. (A) Overview of the media
transfer experimental strategy. Control cells, containing vector alone,
were harvested and exposed to unconditioned DMEM or conditioned
medium collected from cells containing sense and antisense dEGFP
plasmids (S+AS expressing cells). In addition, cells containing sense
and antisense plasmids were re-exposed to their own conditioned
medium. (B) Reduction in dEGFP-mediated cell ﬂuorescence by con-
ditioned medium. The geometric mean ﬂuorescence for control cells
and S+AS cells was determined at day 0 and 5 following exposure to
either unconditioned DMEM or conditioned medium obtained from
S+AS expressing cells (S +AS derived media). The black histograms
indicated control cells and the grey histograms show the S+AS cells.
The error bars represent S.D. (C) The transferable silencing signal is
speciﬁc in recipient cells. The steady-state levels of dEGFP, p53 and b-
actin proteins are shown in two independent experiments involving
exposure of control cells to unconditioned DMEM or conditioned
medium from S+AS cells (arrows).
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duction in dEGFP protein levels. In contrast, no reduction in
dEGFP protein was observed in cells grown in unconditioned
DMEM or medium obtained from cells containing control
plasmids. Furthermore, the speciﬁcity of the mobile signal was
conﬁrmed by the lack of eﬀect on both p53 and b-actin proteinlevels. This suggests that the transferable silencing signal is
speciﬁc for the dEGFP gene. Additional experiments will be
required to determine the nature of the signalling molecule
mediating this speciﬁc suppressive eﬀect.
3.4. Long complementary RNAs suppress endogenous gene
expression
To examine the utility of long complementary RNAs for
controlling the expression of endogenous genes in mammalian
cells, we chose the TP53 gene as a target. This gene encodes the
p53 transcriptional activator protein and can be regulated by
both synthetic and gene-expressed siRNAs [28]. Episomal
plasmids encoding sense and antisense p53 RNAs were gen-
erated and combinations of these plasmids were delivered to
HCT116 colon carcinoma cells. Following selection for cells
containing antisense, sense or both expression plasmids, in-
dependent clones were isolated and examined for p53 protein
levels. As observed for the dEGFP transgene, a larger number
of the clones containing sense and antisense p53 plasmids
132 N. Tran et al. / FEBS Letters 573 (2004) 127–134displayed a reduction in p53 protein compared with those
containing vector alone, sense alone or antisense alone
(Fig. 5A). In addition, as with the transgene target, the clones
selected for maintenance of the sense and antisense p53 ex-
pression plasmids could be classiﬁed into three diﬀerent groups
based on the levels of p53 protein. These results demonstrate
that co-delivery of episomal plasmids encoding long comple-
mentary RNAs can be used to regulate the expression of an
endogenous gene in mammalian cells. Furthermore, this
method results in the generation of an ‘‘epi-allelic’’ series of
clones in which the speciﬁc target gene is expressed at diﬀerent
steady-state levels.
To further examine the underlying mechanism for long com-
plementary RNA-mediated gene silencing, we performed RNA
analyses of clones from the three diﬀerent classes for the level of
TP53 mRNA and the presence or absence of p53-speciﬁc small
RNAs. The steady-state level of TP53 mRNA was found to
correlate with the level of reduction of the p53 protein, sug-
gesting that long complementary RNA co-expression mediated
its silencing eﬀect by reducing or eliminating target mRNA
(Fig. 5B). In addition, those clones displaying the lowest level of
p53mRNAand protein also contained p53-speciﬁc small RNAs
(Fig. 5C). These observations suggest that complementaryRNA
co-expression generates small gene-speciﬁc RNAs, the latter of
which are considered a hallmark of RNAi.4. Discussion
In this study, we report on the development of a method
using episomal plasmids encoding long complementary RNAs
to speciﬁcally suppress foreign and endogenous gene expres-
sion in mammalian cells. We demonstrate that suppression is
dependent on the co-existence of plasmids encoding sense and
antisense RNAs speciﬁc for the target gene sequence. The
observed suppression of gene expression involves target RNA
degradation, reduction in target protein levels and the pro-
duction of gene-speciﬁc small RNAs, all molecular indicators
of RNAi or a RNAi-like mechanism. Interestingly, the gen-
eration of small eﬀector RNAs using this approach was not
reduced by siRNA-mediated suppression of the RNAseIII-like
enzyme Dicer. In addition, the gene silencing eﬀect was shown
to be transferable to other cells not previously exposed to the
sense and antisense RNA-encoding episomal plasmids.
Unlike most other organisms, dsRNA of greater than 30 bp
in length can induce the generalised interferon response in
mammalian cells. This occurs by inactivation of the eukaryote
initiation factor 2a by the dsRNA-dependent protein kinase
PKR. In addition, cells also undergo activation of the 20–
50OAS/RNAseL system leading to non-speciﬁc mRNA degra-
dation. The end result arising from these combined pathways is
cellular apoptosis. The presence of this generalised response has
discouraged the use of longer dsRNA in mammalian cells and
favoured the development of synthetic siRNAs and gene ex-
pression systems compatible with the expression of small
hairpin RNAs [5,7,29]. In spite of this, attempts have been
made to test longer dsRNA in mammalian cells as a trigger for
RNAi with mixed results. In cell types lacking a PKR response
system, in vitro transcribed or gene-expressed dsRNA was
shown to be eﬀective and speciﬁc in mediating gene silencing
[11,30]. In contrast, delivery of in vitro transcribed long dsRNAto the cytoplasm of commonly used mammalian cells, in which
the PKR response was expected to be more robust, appeared to
induce sequence non-speciﬁc eﬀects [31]. Despite these results,
several lines of evidence have emerged suggesting that condi-
tions exist in which longer dsRNA may be used in standard
mammalian cell lines to induce gene-speciﬁc silencing. Gene
constructs designed to express long inverted repeat dsRNA
have been shown to control speciﬁc gene expression in CHO
cells and mice [13]. Co-delivery of sense and antisense RNA-
expressing plasmids leads to increased suppression of speciﬁc
gene expression compared with antisense RNA alone [32].
Furthermore, conditional control of speciﬁc gene expression
was accomplished by co-expression of 290 base sense and an-
tisense RNAs in NIH 3T3 cells [33]. Interestingly, in all studies
using gene-expressed longer dsRNAs, expression of the full-
length RNA or sense and antisense RNAs has not been
demonstrated, suggesting that these RNAs undergo rapid
modiﬁcation. In the present study, we have conﬁrmed and
extended the results from these studies by showing that co-
expression of long complementary RNAs can be used to con-
trol the expression of speciﬁc genes in commonly used cell lines.
The premise behind the current report to controlling gene
expression stems from earlier observations that introducing
sense and antisense plasmids into eukaryotic cells enhances
suppression of a target gene [34]. Co-expression of long sense
and antisense RNAs occurs naturally in mammalian cells and,
in most instances, these complementary RNAs are localised
within the nuclear compartment [35]. Analysis of the human
genome sequence for the presence of complementary RNA
transcripts has identiﬁed a large number of potential RNA
partners, some of which may act as regulators of RNA se-
quences having sequence complementarity [18]. This suggests
that mammalian cells have mechanisms to deal with these long
dsRNAs or use these as mediators of gene regulation. Al-
though the precise mechanism by which long dsRNA results in
gene-speciﬁc silencing remains to be elucidated, several lines of
evidence from the present study suggest a nuclear step. Export
of long dsRNA, formed by hybridisation between the co-
expressed sense and antisense RNAs, to the cytoplasm would
be expected to activate PKR and other global responses and
induce cell death. As shown in this paper, PKR was not acti-
vated in cells showing gene-speciﬁc silencing and no diﬀerences
in cell morphology or cell growth were observed. Attempts to
reverse the gene-speciﬁc silencing eﬀect by siRNA-mediated
reduction of Dicer activity did not result in the loss of gene
suppression by long dsRNA. This suggests that the generation
of the observed small eﬀector RNAs in cells co-expressing long
complementary RNAs, and displaying gene knockdown, oc-
curred in a Dicer-independent manner – for example, within
the nucleus by a Dicer-like activity such as Drosha [25]
or through the microRNA processing pathway [36]. In addi-
tion, the fact that Dicer has been reported as a cytoplasmic
enzyme further supports a nuclear-based step. We propose that
long dsRNA, if formed, is processed in the nucleus by a Dicer-
like enzyme to produce gene-speciﬁc siRNAs that can act ei-
ther in the nucleus or the cytoplasm to induce the degradation
of complementary target mRNA. In this way, the mammalian
cell can accommodate the presence of long dsRNA without
inducing global responses. This is supported by a recent study
aimed at deliberately localising long dsRNA to the nucleus to
mediate tissue-speciﬁc knockdown in mice [37]. The recent
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human genome has predicted that as much as 8% of genes may
be inﬂuenced by antisense [18], with some suggesting that this
may be an underestimate of the extent of antisense transcrip-
tion [38]. Given that the average length of the overlaps in the
sense-antisense pairs is 372 bp, the mammalian cell potentially
contains a highly abundant sub-population of naturally oc-
curring long dsRNAs, some or all of which may be modiﬁed
or processed within the nucleus and block speciﬁc gene
expression.
Studies in non-mammalian organisms have indicated that
gene silencing mediated by dsRNA can be systemic and heri-
table, suggesting that the silencing signal is mobile and cell
non-autonomous. In this way, dsRNA-mediated induction of
gene silencing can lead to the establishment of RNAi in cells
not directly exposed to the dsRNA. The spreading of the si-
lencing eﬀects mediated by RNAi has been shown in transgenic
plants [39], C. elegans [3], and Drosophila S2 culture cells [27].
Little is known about the chemical nature of the signal, how-
ever, current candidates include siRNAs or long dsRNAs
[40,41]. Genetic studies in C. elegans have identiﬁed a trans-
membrane protein encoded by the sid-1 gene that may act as a
channel for the import of the mobile signal [42]. It is interesting
to note that SID-1 homologues are present in mammalian
cells, suggesting the possibility that RNAi-mediated gene si-
lencing in these cells may include a cell non-autonomous
component. In the present study, we demonstrate that condi-
tioned medium isolated from cells containing sense and anti-
sense episomal plasmids, but not control episomes, induces
gene-speciﬁc suppression in cells not previously transfected
with either plasmid. Exposure of the recipient cells to this
medium did not result in the activation of PKR, indicating
that gene silencing was not due to an interferon response.
Furthermore, the observed level of suppression in the recipient
cells was greater than in the original cells, raising the possi-
bility that the mobile signal was possibly ampliﬁable. Both the
presence of a sequence-speciﬁc mobile signal and a possible
mechanism of ampliﬁcation are consistent with the features
used to deﬁne systemic silencing in other organisms. One al-
ternative explanation is the release of episomal plasmids into
the medium in the original culture and transfection of recipient
cells with these plasmids. This scenario is highly unlikely, since
plasmid uptake requires transfection reagents and the sense
and antisense plasmids would need to enter the same cell to
mediate gene silencing. The precise nature of the mobile si-
lencing signal remains to be determined and the tissue culture
model presented here should be useful in its characterisation.
In this study, we have shown for the ﬁrst time that expres-
sion of long complementary RNAs from episomal plasmids
mediates speciﬁc gene silencing in mammalian cells. This ap-
proach provides an alternative to other strategies for inducing
dsRNA-mediated gene regulation with the beneﬁt of sustained
gene silencing, as opposed to transient suppression. In addi-
tion, the use of long RNA strands does not require pre-de-
termination of the sensitive site for targeted regulation of gene
expression, as required with siRNAs and gene expression
methods using shRNAs [7]. A further advantage of using
episomal vectors to transcribe either sense or antisense RNA is
the ﬂexibility to utilise plasmid segregation to conditionally
convert from a suppressive phenotype to a normal phenotype
in a relatively short time period. The generation of cell clonesdisplaying varying levels of target gene expression provides an
‘‘epi-allelic’’ series useful in studying gene function [43]. It is
anticipated that complementary RNA co-expression will pro-
vide a useful alternative approach to inducing RNAi (or
RNAi-like)-mediated gene regulation in mammalian cells.
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